Evaluating Circulating DNA to Predict Residual Disease After Potentiated Radiotherapy for Locally Advanced Head and Neck Cancer
Led by Centre Jean Perrin · Updated on 2026-09-11
63
Participants Needed
4
Research Sites
117 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating the use of circulating DNA detection to predict residual disease in patients with locally advanced head and neck squamous cell carcinomas HNSCCs treated with potentiated radiotherapy. Locally advanced HNSCCs have high rates of locoregional failure, and current imaging methods like PET-CT have limitations in accurately detecting residual disease due to false positives caused by inflammation. This study aims to assess whether circulating tumor DNA ctDNA, including circulating HPV16 viral DNA cvDNA, can provide more reliable information about treatment response and residual disease.
Participants will have blood samples collected twice once before treatment and again three months after radiochemotherapy if imaging shows an incomplete response. The study focuses on patients undergoing potentiated radiotherapy combined with chemotherapy regimens including Docetaxel, Platinum, and 5-Fluorouracil. This single-arm, open-label, multicenter study monitors ctDNA and compares it with PET-CT results to evaluate its value in detecting residual disease and predicting patient outcomes.
During the study, participants will undergo PET-CT scans and blood sampling to measure ctDNA levels. Researchers will track the rate of incomplete cervical lymph node response on PET-CT and the presence of circulating DNA three months after treatment. Additional assessments include evaluating concordance between tumor and circulating DNA profiles, reproducibility of imaging interpretations, and long-term monitoring of clinical and pathological features. The study extends up to 66 months to observe outcomes and includes regular clinical follow-up to assess the prognostic value of ctDNA and HPV-related markers.
CONDITIONS
Brief Title
Prediction of Residual Disease by Circulating DNA Detection After Potentiated Radiotherapy for Locally Advanced Head and Neck Cancer
Research Team
A
Angeline GINZAC COUVÉ, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Histologically confirmed squamous cell carcinoma with lymph node involvement, never treated before
Squamous cell carcinoma p16 positive or negative, stage III (N1), IVa or IVb, or oropharyngeal carcinoma p16 positive stage I or II, with N1 minimum
Cancer located in oral cavity, oropharynx, hypopharynx, larynx, or cervical adenopathies without primary tumor
Availability of tissue samples before treatment
Detectable circulating DNA in initial blood sample
Patient consents to participate
Affiliated with French social security system
You will not qualify if you...
Tumors of nasopharynx, sinuses, nasal cavity, salivary glands, or thyroid cancer
Treatment by radiotherapy alone
Contraindication to cervical lymph node dissection
Metastatic disease (stage IVc)
Previous treatment for head and neck cancer
Other cancer history in last 3 years (except certain localized cancers)
Pregnant or breastfeeding women
Patients under guardianship or curatorship
Psychological, social, or geographical conditions that prevent compliance or follow-up
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment and Monitoring
Duration - Up to 66 months
Participants undergo potentiated radiotherapy combined with chemotherapy. Blood samples are collected at the start and three months after treatment if imaging shows incomplete response. PET-CT scans are performed to assess lymph node response.
Multiple visits for imaging and blood sampling over follow-up
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Similar Trials
Evaluating Circulating DNA to Detect Residual Disease After Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
Phase 12 Study of Gabapentin and Intranasal Ketamine for Preventing and Treating Pain in Adults with Locally Advanced Head and Neck Cancer Undergoing Chemoradiation
Comparing Neoadjuvant Immunochemotherapy Plus Surgery Versus Standard Surgery and Adjuvant Therapy
for Locally Advanced Oral Squamous Cell Carcinoma
A Multicenter Randomized Phase 3 Trial
Evaluating Circulating DNA to Predict Residual Disease After Potentiated Radiotherapy for Locally Advanced Head and Neck Cancer
Phase I Study of Thermotherapy Added to Standard Chemoradiotherapy or Radiotherapy for Locally Advanced Head and Neck Cancer
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Prediction of residual disease using circulating DNA detection after potentiated radiotherapy for locally advanced head and neck cancer (NeckTAR): a study protocol for a prospective, multicentre trial.
Angeline Ginzac, Marie-Céleste Ferreira, Anne Cayre...